Shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report) shot up 0.8% during mid-day trading on Monday . The stock traded as high as $9.15 and last traded at $9.05. 79,971 shares were traded during mid-day trading, a decline of 23% from the average session volume of 104,232 shares. The stock had previously closed at $8.98.
Analyst Ratings Changes
Separately, Wall Street Zen downgraded shares of LogicBio Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th.
View Our Latest Research Report on LOGC
LogicBio Therapeutics Trading Down 0.4%
Institutional Investors Weigh In On LogicBio Therapeutics
An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. boosted its stake in shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Free Report) by 284.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 526,673 shares of the company’s stock after purchasing an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned 2.00% of LogicBio Therapeutics worth $3,676,000 at the end of the most recent quarter. Institutional investors own 46.05% of the company’s stock.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.
Featured Articles
- Five stocks we like better than LogicBio Therapeutics
- Palo Alto Networks Accelerates Growth 31% on AI Demand
- NVIDIA, Marriott, and PCA Just Delivered Big News for Income Investors
- Motorola’s $1.5B Bet to Own the Skies
- AI’s Power Crunch Is Putting Uranium Energy Back on Investors’ Watchlists
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
